Hi everyone,

I'll make this much shorter, since I didn't get any response from my post
titled "run-around from Glaxo on Ecotrin".  I apologize for my long posts,
but I try to be specific so there are no misunderstandings.

Is it true that enteric coated aspirin will "topically" (i.e., by direct
contact) damage the duodenum mucosa (since it is designed to dissolve in the
duodenum in lieu of the stomach) just as bad as non-enteric coated aspirin
would "topically" damage the stomach mucosa, and if so what is the advantage
of taking it (in other words it "topically" damages your duodenum instead of
your stomach).  The box (whether it is brand name or generic) says something
like "safely designed to dissolve in the small intestine".

I understand the systemic damage by prostaglandin blocking (which is the
mechanism by which NSAIDS work), but that is a separate issue which will
occur regardless of any coating on the NSAID. And based on my studies, the
prostaglandin blocking is more damaging to the stomach/duodenum than the
topical damage anyway - do you agree.

If what I am getting at is true, how does the FDA allow this crap (which in
my opinion is false advertising).  I tried to get a response from Glaxo from
their scientific department and they never called me back (which I knew they
wouldn't - they don't care about one little guy like me - its a sad state of
affairs what the world has become).

There must be at least one pharmacist that can address my concern.  Your
response would be greatly appreciated.  Thanks.

Pete